Illustration of damaged spinal cord interwoven with glowing strands of RNA and minocycline molecules interacting with RNA.

Unlocking Spinal Cord Secrets: How LncRNAs Could Revolutionize Neuropathic Pain Treatment

Lena Kashyap monogram
Lena Kashyap in Health & Wellness October 2026 • 5 min read.

"New research unveils the role of long non-coding RNAs (LncRNAs) in spinal cord nerve injury and the potential of minocycline to modulate these effects, opening doors to novel pain therapies."


Neuropathic pain is a persistent and often debilitating condition affecting millions worldwide. Current treatments frequently fall short, highlighting the urgent need for innovative therapeutic approaches. Recent research has begun to focus on the complex molecular mechanisms underlying neuropathic pain, including the potential involvement of long non-coding RNAs (LncRNAs).

LncRNAs are a class of RNA molecules that, unlike messenger RNAs, do not code for proteins. Instead, they play crucial regulatory roles in various biological processes, including gene expression. Emerging evidence suggests LncRNAs may be key players in the development and maintenance of chronic pain states.

This article delves into a study investigating the expression of LncRNAs in the spinal cord of mice with spared nerve injury (SNI), a model of neuropathic pain. The research also examines the effects of minocycline, an antibiotic with anti-inflammatory properties, on LncRNA expression, offering new insights into potential therapeutic targets for neuropathic pain.

AI Search Multiple angles on this topic

The Burden of Neuropathic Pain

Neuropathic pain can substantially affect daily functioning, comfort, and quality of life. Its causes and severity vary, so the overall impact differs among individuals. Understanding these effects is important when evaluating potential treatments such as lncRNA-based approaches.

Existing Treatment Challenges

Current management generally relies on established medications and other clinical interventions selected according to the patient's symptoms and condition. These approaches may not provide consistent relief for everyone and can involve limitations or unwanted effects. This leaves room for research into more targeted biological strategies.

From Symptoms to Molecular Targets

Research into neuropathic pain has gradually expanded from symptom control toward understanding the biological mechanisms behind nerve-related pain. Advances in molecular biology have created interest in previously overlooked regulators, including long non-coding RNAs. This shift provides the foundation for investigating lncRNAs as possible therapeutic targets.

Decoding LncRNAs: Key Regulators in Spinal Cord Nerve Injury

Illustration of damaged spinal cord interwoven with glowing strands of RNA and minocycline molecules interacting with RNA.

The study, published in the Journal of Pain Research, employed microarray analysis to identify LncRNAs and messenger RNAs (mRNAs) that are differentially expressed in the spinal cord of mice following spared nerve injury (SNI). This comprehensive approach revealed a significant number of LncRNAs and mRNAs whose expression levels were altered in response to SNI.

Researchers identified 22,213 LncRNAs and 19,528 mRNAs in the spinal cord. Further analysis revealed that the abundance of 183 LncRNAs and 102 mRNAs were significantly modulated by both SNI and the administration of minocycline. This suggests that these molecules play a crucial role in the development of neuropathic pain and the response to treatment.

  • Differentially Expressed LncRNAs: The study pinpointed specific LncRNAs that exhibited altered expression patterns in response to nerve injury, suggesting their involvement in pain pathways.
  • Minocycline's Modulating Effect: The research showed that minocycline, known for its anti-inflammatory properties, could influence the expression of certain LncRNAs, potentially contributing to its pain-relieving effects.
  • Intergenic LncRNAs: The largest category of differentially expressed LncRNAs identified were intergenic LncRNAs, highlighting the importance of these regulatory molecules in nerve injury response.
AI Search Multiple angles on this topic

Rapidly Advancing RNA Research

Recent reviews describe continued progress in studying lncRNAs in neuropathic pain, supported by the growing availability of high-throughput sequencing and bioinformatics methods. Other reviews focus on neuropathic pain pathophysiology, current treatment options, and the possible translation of RNA biomarkers into tools for diagnosis and treatment monitoring. Together, these publications present lncRNA and other RNA-based findings as an active but still developing research area. (Reference URL 1; Reference URL 2)

Evidence Still Developing

Interest in lncRNAs does not yet establish that they are ready for routine neuropathic pain treatment. Findings from molecular and experimental research may not translate directly into safe, effective clinical therapies. Questions about validation, delivery, treatment specificity, and long-term effects remain important limitations.

Conventional Options and Emerging Targets

Evidence-based approaches to neuropathic pain include pharmacological treatments, neurostimulation, psychotherapy, and interventional modalities. A systematic review covers drug classes such as antidepressants, anticonvulsants, opioids, cannabis, and emerging agents directed at specific receptors and neurotransmitters. Recent treatment reviews emphasize that oral, topical, and interventional options differ in benefits, risks, and appropriate clinical contexts, so treatment selection requires balancing evidence with patient needs. (Reference URL 1; Reference URL 2)

To validate the microarray findings, the researchers performed quantitative real-time polymerase chain reaction (qRT-PCR) analysis on three selected LncRNAs (NR_015491, ENSMUST00000174263, and ENSMUST00000146263). The qRT-PCR results confirmed the expression changes observed in the microarray, strengthening the reliability of the findings. The study also found that SNI-induced gene regulations might be involved in the activities of cytokines (IL17A and IL17F) and chemokines (CCL2, CCL5, and CCL7), whereas minocycline might exert a pain-alleviating effect on mice through actin binding, thereby regulating nociception by controlling the cytoskeleton.

The Future of Pain Relief: Targeting LncRNAs

This research provides compelling evidence for the involvement of LncRNAs in the development of neuropathic pain following spinal cord nerve injury. By identifying specific LncRNAs that are modulated by both nerve injury and minocycline treatment, the study opens new avenues for therapeutic intervention.

AI Search Multiple angles on this topic

LncRNAs as Pain Regulators

Research reviewed in the cited article reports that peripheral nerve injury can dysregulate lncRNAs in regions involved in pain. It discusses potential mechanisms through which these altered lncRNAs may contribute to the pathogenesis of neuropathic pain. This supports viewing lncRNAs not only as biomarkers but also as possible targets for future investigation. tandfonline.com

Toward RNA-Based Therapies

Bibliometric research identifies evolving trends, research hotspots, and future directions in microRNA-based therapy for neuropathic pain. Although microRNAs are distinct from lncRNAs, this work illustrates the broader momentum behind RNA-focused therapeutic research. Market analysis cited in the source material reports that the neuropathic pain market was valued at USD 8.15 billion in 2025 and is projected to reach USD 18.07 billion by 2035, at a reported CAGR of 8.29%. (Reference URL 1; Reference URL 2)

Translation Beyond the Laboratory

Progress in lncRNA research will need to address more than biological discovery alone. Potential therapies must also demonstrate reliable diagnosis or patient selection, practical delivery, safety, and meaningful clinical benefit. Differences in access to specialized testing and treatment could further affect how quickly emerging approaches reach patients.

Pain Biology and Patient Experience

A review reports that many studies have identified changes in lncRNA expression and important roles for lncRNAs in chronic pain models. It examines lncRNA alterations after spinal cord injury and peripheral nerve injury and discusses specific lncRNAs that may contribute to the etiology and pathophysiology of neuropathic pain. These findings may improve understanding of why patients experience persistent nerve-related pain, while remaining part of an evolving research field. ncbi.nlm.nih.gov

The findings suggest that targeting LncRNAs could offer a novel approach to pain management. Future research should focus on further elucidating the precise mechanisms by which these regulatory molecules contribute to neuropathic pain and on developing strategies to selectively modulate their expression.

Ultimately, this research could pave the way for the development of more effective and targeted therapies for neuropathic pain, improving the lives of millions suffering from this chronic condition. The potential to influence cytokine activities and actin-binding through LncRNAs represents a promising direction for future pain relief strategies.

The weight of this mouse-model evidence

Animal study (level 5 of 8)

Because this was an animal study, it can show how minocycline treatment and spinal-cord RNA patterns coincided in a spared nerve injury model, but it cannot establish that the same effects occur in people. The study card identifies the population as mice and the design tier as animal.[1]

The spinal-cord measurements were taken seven days after injury, so they capture a defined, short-term window rather than showing how these patterns develop over longer periods.[1]

What the RNA and threshold findings mean

Together, the findings link minocycline treatment with both a changed mechanical pain response and shifts in spinal-cord RNA abundance. They make RNA regulation a plausible part of the pattern, but do not show that the RNA changes caused the threshold difference.[1] [2]

The authors’ functional analysis points to possible involvement of inflammatory signaling after injury and cytoskeletal regulation with minocycline. These are proposed interpretations of the expression data, not demonstrated mechanisms.[1]

The authors describe the work as an initial step toward genetic therapies, reflecting that the findings identify candidates for investigation rather than an established treatment approach.[1] [2]

What keeps the RNA interpretation unsettled

  • The paper says the available evidence was too limited to establish minocycline’s actual role, which constrains interpretation of its treatment effects.[2]
  • The authors call for confirmation of the candidate lncRNAs’ roles in neuropathic pain; their involvement is not established by this study alone.[2]

The study at a glance: spinal cord after spared nerve injury

Study designAnimal study[1]
PopulationMice in a spared nerve injury model of neuropathic pain[1]
SettingIpsilateral L4-L5 spinal cord[1]
Duration7 days after SNI[1]
p-valueP<0.001[1]
FundingNational Natural Science Foundation of China (number 31100805) and Project of Science and Technology New Star in Zhujiang Guangzhou City (number 2012J2200036)[1]
Times cited32[1]

How this spinal-cord profile compares with later work

Other injury models have also yielded altered lncRNA profiles, but the reported totals differ across models and methods; these figures are not direct replications of the minocycline comparison.[2] [3] [4]

What follow-up evidence would clarify

  • Would independent experiments confirm that the candidate lncRNAs contribute to pain-related changes, rather than simply accompanying them?[2]

Sources

  1. LncRNA expression in the spinal cord modulated by minocycline in a mouse model of spared nerve injury (Informa UK Limited, 2017)
  2. LncRNA expression in the spinal cord modulated by minocycline in a mouse model of spared nerve injury (Europe PMC, 2017)
  3. Identification of the Spinal Expression Profile of Non-coding RNAs Involved in Neuropathic Pain Following Spared Nerve Injury by Sequence Analysis. (pubmed.ncbi.nlm.nih.gov)
  4. Functional roles of lncRNAs and its potential mechanisms in neuropathic pain (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.2147/jpr.s147055, Alternate LINK

Title: Lncrna Expression In The Spinal Cord Modulated By Minocycline In A Mouse Model Of Spared Nerve Injury

Subject: Anesthesiology and Pain Medicine

Journal: Journal of Pain Research

Publisher: Informa UK Limited

Authors: Zihao Liu, Ying Liang, Honghua Wang, Zhenhe Lu, Jinsheng Chen, Qiaodong Huang, Lei Sheng, Yinghong Ma, Huiying Du, Qingjuan Gong

Published: 2017-10-01

Everything You Need To Know

1

What exactly are LncRNAs, and why are they important in the context of neuropathic pain?

LncRNAs, or long non-coding RNAs, are RNA molecules that do not code for proteins. Instead, they regulate biological processes, notably gene expression. In the context of neuropathic pain, research indicates that LncRNAs play a key role in both the development and maintenance of chronic pain states, making them potential therapeutic targets.

2

How did the researchers study the role of LncRNAs in spinal cord nerve injury, and what methods did they use?

The research used spared nerve injury (SNI) in mice as a model for neuropathic pain. By analyzing the spinal cord tissue using microarray analysis, researchers identified that the expression of 183 LncRNAs and 102 mRNAs were significantly altered by both SNI and the administration of minocycline. Quantitative real-time PCR (qRT-PCR) was then used to validate the microarray findings for selected LncRNAs, confirming their differential expression.

3

How does minocycline, an antibiotic, affect LncRNA expression in the spinal cord, and what does this mean for pain relief?

Minocycline is an antibiotic known for its anti-inflammatory properties. The research indicates that minocycline can modulate the expression of certain LncRNAs in the spinal cord after nerve injury. This suggests that minocycline's pain-relieving effects may be partly due to its influence on the activity of LncRNAs, potentially through actin binding which regulates nociception by controlling the cytoskeleton.

4

What are intergenic LncRNAs, and why are they significant in the study of nerve injury?

Intergenic LncRNAs are LncRNAs located between genes and were found to be the largest category of differentially expressed LncRNAs identified in the study following spared nerve injury (SNI). This highlights their significant role in the response to nerve injury. Further research into these specific intergenic LncRNAs could provide deeper insights into the mechanisms driving neuropathic pain and potential therapeutic targets.

5

Besides LncRNAs, what other molecular mechanisms involving cytokines, chemokines, and the cytoskeleton were identified, and how might they be relevant to treating neuropathic pain?

The research suggests that SNI-induced gene regulations might be involved in the activities of cytokines (IL17A and IL17F) and chemokines (CCL2, CCL5, and CCL7). These molecules are known to mediate inflammation and immune responses. The study also proposes that minocycline might alleviate pain by affecting actin binding, thereby regulating nociception via control of the cytoskeleton. These complex interactions between LncRNAs, inflammatory mediators, and cellular structures could pave the way for targeted therapies that disrupt the pain pathway at multiple levels.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.